SCHEMBL13613670

SCHEMBL13613670

Cc1cc(F)cc2c1C(=O)N(CC1CC1)C2

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.42
PIK3CA P42336 2/20 0.42
PIK3CG P48736 2/20 0.42
PARP1 P09874 6/20 0.38
PARP2 Q9UGN5 2/20 0.38
HTR1A P08908 1/20 0.37
HTR2A P28223 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
NR1I2 O75469 1/20 0.36
UGCG Q16739 1/20 0.36
GRIA2 P42262 1/20 0.34
GRIN2A Q12879 1/20 0.34
KCNH2 Q12809 2/20 0.33
GRM2 Q14416 2/20 0.33
BRD4 O60885 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1001568 0.83 PIK3CD (0.42) PIK3CDPIK3CAPIK3CGPARP1PARP2
SCHEMBL2023396 0.83 PARP1 (0.38) PIK3CDPIK3CAPIK3CGPARP1PARP2
SCHEMBL1001933 0.83 PIK3CG (0.42) PIK3CDPIK3CAPIK3CGPARP1PARP2
SCHEMBL2024821 0.83 PARP1 (0.38) PIK3CDPIK3CAPIK3CGPARP1PARP2
SCHEMBL8271584 0.83 PIK3CD (0.42) PIK3CDPIK3CAPIK3CGPARP1PARP2
SCHEMBL29314729 0.81 PIK3CG (0.41) PIK3CDPIK3CAPIK3CGPARP1PARP2
SCHEMBL24469663 0.77 PARP1 (0.56) PIK3CDPIK3CAPIK3CGPARP1PARP2
SCHEMBL1002130 0.76 PARP1 (0.50) PARP1PARP2HTR1AHTR2ATMEM97
SCHEMBL1002883 0.76 PARP1 (0.47) PIK3CDPIK3CAPIK3CGPARP1PARP2
SCHEMBL13613660 0.75 PARP1 (0.48) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 PIK3CD 1029/4885PIK3CA 1203/4885PIK3CG 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.